^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Labvax 3(22)-23
i
Other names: Labvax 3(22)-23
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
LabyRx Immuno-Oncology
Drug class:
Immunostimulant
Related drugs:
7ms
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma (clinicaltrials.gov)
P1/2, N=77, Recruiting, Tianhong Li | Phase classification: P1 --> P1/2 | N=10 --> 77 | Trial completion date: Sep 2027 --> Jan 2030 | Trial primary completion date: Sep 2023 --> Jan 2026
Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF mutation • MET mutation
|
Keytruda (pembrolizumab) • Labvax 3(22)-23 • Leukine (sargramostim)
2years
A first-in-human, phase I, open-label study of a novel cancer vaccine labvax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas. (ASCO 2022)
Sargramostim, a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF), is given as an immunostimulator with LabVax 3(22)-23 to boost the antitumor immune response. After completion of study treatment, patients are followed every 3 months for 1 year. Two patients are enrolled at the time of submission.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CSF2 (Colony stimulating factor 2)
|
PD-L1 expression
|
Labvax 3(22)-23 • Leukine (sargramostim)
Share via
